Replidyne, a biopharmaceutical company developing a new class of antibiotics in collaboration with Forest Laboratories, announced the terms for its IPO on Tuesday. According to an amended SEC filing, the Louisville, CO based company plans to offer 5 million shares at a range of $14 - $16 and has a proposed market cap of $395 million. Joint book-running managers Merrill Lynch and Morgan Stanley are expected to price the deal during the week of June 26.
